Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ascendis Pharma A/S

174.96
-1.5300-0.87%
Post-market: 174.960.00000.00%17:23 EDT
Volume:387.28K
Turnover:67.87M
Market Cap:10.59B
PE:-27.80
High:177.18
Open:176.42
Low:173.78
Close:176.49
Loading ...
May 12, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
May 07, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
May 07, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
May 06, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
May 05, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Mar 07, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Mar 07, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Mar 07, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Mar 05, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Mar 05, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Mar 04, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Mar 04, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Mar 04, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Mar 04, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Mar 04, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Mar 04, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Mar 04, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Mar 04, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Mar 04, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Mar 04, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities